

**SPEAKER 1:** But what is indication at this point for this new drug? Based off FDA approval, patients that been six months on treatment and they failed, means sputum is not converted, is indication to start this new medication on top of previous medications. The caveat here is what about other medications? What about drug resistance?

So I would suggest for every patient that you want to start treatment, get susceptibility in the first place, and after six months that you call the patient failure, request another susceptibility. And based off drug susceptibility test, find it out that if there is drug resistance developed already for macrolide, rifampin, or ethambutol, substitute with two new medications, including liposomal amikacin. People use clofazimine, people use linezolid, and many other medications, including bedaquiline in that setting, too. However, at this point, only FDA approved medication is liposomal amikacin inhaler.